# Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer

> **NCT03799679** · PHASE4 · UNKNOWN · sponsor: **Fudan University** · enrollment: 60 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Chemotherapeutic Agent

## Key facts

- **NCT ID:** NCT03799679
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-26
- **Primary completion:** 2019-11-30
- **Final completion:** 2020-02-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03799679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03799679, "Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03799679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*